NASDAQ:APLT Applied Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Applied Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.36 +0.41 (+1.71 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$23.85Now: $24.36▼$24.8850-Day Range$22.51MA: $25.43▼$30.6852-Week Range$9.60Now: $24.36▼$57.39Volume242,403 shsAverage Volume227,315 shsMarket Capitalization$546.52 millionP/E RatioN/ADividend YieldN/ABeta0.56 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.20, Applied Therapeutics has a forecasted upside of 126.6% from its current price of $24.36.Amount of Analyst CoverageApplied Therapeutics has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesApplied Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApplied Therapeutics has received 59 “underperform” votes. (Add your “underperform” vote.)Community SentimentApplied Therapeutics has received 54.13% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote “Outperform” if you believe APLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,210,239.00 in company stock.Percentage Held by InsidersOnly 31.50% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions52.58% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Applied Therapeutics are expected to decrease in the coming year, from ($3.56) to ($3.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLT Previous Symbol CUSIPN/A CIKN/A Webwww.appliedtherapeutics.com Phone212-220-9226Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees4 Outstanding Shares22,435,000Market Cap$546.52 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $24.36 +0.41 (+1.71 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive APLT News and Ratings via Email Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions How has Applied Therapeutics' stock been impacted by Coronavirus (COVID-19)? Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, APLT shares have decreased by 17.7% and is now trading at $24.36. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Applied Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Therapeutics. When is Applied Therapeutics' next earnings date? Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Applied Therapeutics. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics (NASDAQ:APLT) issued its earnings results on Tuesday, August, 11th. The company reported ($1.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.58. View Applied Therapeutics' earnings history. What price target have analysts set for APLT? 6 brokers have issued 1-year price targets for Applied Therapeutics' stock. Their forecasts range from $43.00 to $65.00. On average, they anticipate Applied Therapeutics' share price to reach $55.20 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price. View analysts' price targets for Applied Therapeutics. Are investors shorting Applied Therapeutics? Applied Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,610,000 shares, an increase of 32.0% from the July 15th total of 1,220,000 shares. Based on an average trading volume of 243,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 12.6% of the company's stock are sold short. View Applied Therapeutics' Short Interest. Who are some of Applied Therapeutics' key competitors? Some companies that are related to Applied Therapeutics include Opko Health (OPK), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), I-Mab (IMAB), Corcept Therapeutics (CORT), Zymeworks (ZYME), Humanigen (HGEN), Eidos Therapeutics (EIDX), CytoDyn (CYDY), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH), Seres Therapeutics (MCRB), Madrigal Pharmaceuticals (MDGL), Uniqure (QURE) and Akcea Therapeutics (AKCA). View all competitors. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include NVIDIA (NVDA), Verizon Communications (VZ), Walt Disney (DIS), Pfizer (PFE), AT&T (T), Advanced Micro Devices (AMD), Broadcom (AVGO), Alteryx (AYX), Boeing (BA) and Enbridge (ENB). Who are Applied Therapeutics' key executives? Applied Therapeutics' management team includes the following people: Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)Dr. Riccardo Perfetti, Chief Medical Officer (Age 59) When did Applied Therapeutics IPO? (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager. What is Applied Therapeutics' stock symbol? Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT." Who are Applied Therapeutics' major shareholders? Applied Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (8.72%), Orbimed Advisors LLC (5.43%), Driehaus Capital Management LLC (3.41%), Vanguard Group Inc. (2.78%), Emerald Advisers LLC (1.81%) and Emerald Mutual Fund Advisers Trust (1.60%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends for Applied Therapeutics. Which major investors are selling Applied Therapeutics stock? APLT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Orbimed Advisors LLC. Company insiders that have sold Applied Therapeutics company stock in the last year include Joel S Marcus, Leslie D Funtleyder, and Shoshana Shendelman. View insider buying and selling activity for Applied Therapeutics. Which major investors are buying Applied Therapeutics stock? APLT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Bamco Inc. NY, Driehaus Capital Management LLC, Kore Private Wealth LLC, Emerald Advisers LLC, Candriam Luxembourg S.C.A., UBS Group AG, and Vanguard Group Inc.. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter. View insider buying and selling activity for Applied Therapeutics. How do I buy shares of Applied Therapeutics? Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Applied Therapeutics' stock price today? One share of APLT stock can currently be purchased for approximately $24.36. How big of a company is Applied Therapeutics? Applied Therapeutics has a market capitalization of $546.52 million. Applied Therapeutics employs 4 workers across the globe. What is Applied Therapeutics' official website? The official website for Applied Therapeutics is www.appliedtherapeutics.com. How can I contact Applied Therapeutics? Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
